Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited (LINCOLN) is a micro-cap Healthcare company valued at ₹1,095 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Lincoln Pharmaceuticals Limited last traded at ₹557.95, up 2.77% on the day.

Recent developments

On 2026-08-13, Lincoln Pharma's stock jumped after reporting a 31% year-over-year increase in quarterly profit to ₹36 crore, reflecting strong performance in the latest quarter.

Financial performance

The company's annual revenue rose 7.7% to ₹671 crore, while annual net profit increased 7.2% to ₹88 crore. The latest quarter saw revenue rise 15.1% to ₹177 crore and net profit jump 30.9% to ₹36 crore compared to the same quarter a year earlier. The net profit margin slightly declined to 13.1% from 13.2% in the prior year, and return on equity was 0.0%.

Valuation multiples

The stock trades at 11.4 times earnings, a discount to the Healthcare median of 32.0, 1.68 times book value. It yields 0.3%.

Things to watch

The stock is 29.1% below its 52-week high, and return on equity was 0.0%, indicating potential challenges in generating returns for shareholders. The net profit margin narrowed by 0.1 percentage points to 13.1%.

Where it stands

Lincoln Pharmaceuticals Limited ended the latest quarter with revenue of ₹177 crore and net profit of ₹36 crore, showing strong growth compared to the same quarter a year earlier. The stock's performance and financial metrics highlight both recent gains and ongoing challenges in profitability and return generation.

Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.